Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496646 | 0.79 | NPY1R (0.44) | SLC6A2SLC6A4SLC6A3ALDH1A1GLA | |
| SCHEMBL21312057 | 0.77 | MCHR1 (0.51) | SLC6A2SLC6A4SLC6A3ALDH1A1GLA | |
| SCHEMBL10427598 | 0.77 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3ALDH1A1GLA | |
| SCHEMBL1496601 | 0.76 | NPY1R (0.47) | SLC6A2SLC6A4SLC6A3ALDH1A1GLA | |
| SCHEMBL13696497 | 0.76 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3ALDH1A1GLA | |
| SCHEMBL27784290 | 0.76 | TRPC6 (0.48) | ALDH1A1 | |
| SCHEMBL15610913 | 0.76 | SCD (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15610914 | 0.76 | SCD (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15610915 | 0.76 | SCD (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1496734 | 0.75 | NPY1R (0.46) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751877-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160024088-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders | PFIZER INC. | 2016-01-28 | — | — | US | disclosed |
| US-9193726-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150072990-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders | PFIZER INC. | 2015-03-12 | — | — | US | disclosed |
| US-8916564-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140088111-A1 | Novel Bicyclic Pyridinones | PFIZER INC. (US) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072990-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders | PRNP, SNCA, PSEN1 | SLC6A2 332/4885SLC6A4 335/4885SLC6A3 379/4885 |
| US-20140088111-A1 | Novel Bicyclic Pyridinones | CYP2B6, CYP2D6, CYP2C19 | SLC6A2 683/4885SLC6A4 488/4885SLC6A3 1008/4885 |
| US-20160024088-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders | PRNP, SNCA, PSEN1 | SLC6A2 332/4885SLC6A4 335/4885SLC6A3 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.